. 2012 Mar 9;8:105–130. doi: 10.2147/TCRM.S29830

Table B.

Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or discontinuing treatment in the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

Trial	Intervention		Control		Relative risk (95% CI)

	N	Pooled (95% CI)	N	Pooled (95% CI)
Sustained virologic response
Naïve patients
Jacobson et al8	271/363	72% (66%–77%)	158/361	44% (40%–47%)	1.71 (1.50–1.95)
	250/364	72% (66%–77%)	158/361	44% (40%–47%)	1.71 (1.50–1.95)
Relapse
Naïve patients
Jacobson et al8	27/314	9% (7%–12%)	64/229	28% (24%–32%)	0.32 (0.24–0.43)
	28/295	9% (7%–12%)	64/229	28% (24%–32%)	0.32 (0.24–0.43)
Discontinuation
Naïve patients
Jacobson et al8	95/363	27% (24%–31%)	159/361	44% (40%–48%)	0.62 (0.54–0.72)
	104/364	27% (24%–31%)	159/361	44% (40%–48%)	0.62 (0.54–0.72)

Abbreviation: CI, confidence interval.